Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial

Pharmaceuticals

Pharmaceuticals refer to medicinal drugs used for the diagnosis, treatment, and prevention of diseases. The pharmaceutical industry encompasses research, development, manufacturing, and distribution of prescription and over-the-counter medications. It is a critical component of global healthcare systems and a major sector in financial markets, influencing public health outcomes and investment trends.

Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Bank of America Spends $250 Million a Year on Ozempic and Other GLP-1 Drugs, CEO Calls It 'a Good Investment'
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

Pharmaceuticals Recent News

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.
Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion
Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion
Eli Lilly plans over $1 billion investment in India to expand drug manufacturing, partnerships, and a new Hyderabad facility.
Why Is Nektar Therapeutics Stock Trading Higher On Thursday? (CORRECTED)
Why Is Nektar Therapeutics Stock Trading Higher On Thursday? (CORRECTED)
Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow.
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment
AbbVie will acquire Gilgamesh's lead psychedelic drug for major depression in a deal worth up to $1.2 billion, following promising Phase 2 results.
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
Cognition Therapeutics Inc (NASDAQ: CGTX) continued to gain 12.10% in after-hours trading on Thursday, after a 20.82% surge during regular market hours.
What's Going On With Viking Therapeutics Stock On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
What's Going On With Verastem Oncology Stock On Monday?
What's Going On With Verastem Oncology Stock On Monday?
Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved